% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Lfling:298230,
author = {L. L. Löfling and N. C. Støer and E. K. Sloan and S.
Nafisi and R. T. Fortner$^*$ and E. Botteri},
title = {{B}eta-blockers and epithelial ovarian cancer survival: {A}
{N}orwegian population-based cohort study.},
journal = {International journal of cancer},
volume = {157},
number = {1},
issn = {0020-7136},
address = {Bognor Regis},
publisher = {Wiley-Liss},
reportid = {DKFZ-2025-00237},
pages = {86-94},
year = {2025},
note = {2025 Jul 1;157(1):86-94},
abstract = {Cancer diagnosis and therapy cause stress to the body.
Preclinical studies have shown that stress hormones can
stimulate tumor progression and metastasis by interacting
with β-adrenergic receptors, and that β-blockers can
inhibit those processes. We assessed if β-blocker use was
associated with survival in a nationwide cohort of women
with epithelial ovarian cancer (EOC). We identified all
women aged ≥40 years who underwent EOC surgery in
2004-2018 in Norway through the Cancer Registry of Norway.
We estimated the association between peri-diagnostic and
post-diagnostic β-blocker use and survival. We used Cox
models, adjusted for sociodemographic and health factors,
and reported hazard ratios (HRs) and $95\%$ confidence
intervals (CIs). The difference in overall survival time
between β-blocker users and non-users was estimated as the
difference in restricted mean survival time at 5 years after
diagnosis using flexible parametric models. We included 3911
women with EOC; 540 $(14\%)$ used β-blockers at diagnosis,
1672 $(43\%)$ died of the disease, and 1882 $(48\%)$ died
overall. We found an association between peri-diagnostic
β-blocker use and longer EOC-specific survival (HR = 0.85,
$95\%CI$ 0.73-1.00; p-value = 0.048), and an indication of
an association with overall survival (HR = 0.89, $95\%CI$
0.77-1.02; p-value = 0.101). Analysis of post-diagnostic
β-blocker use, which included only women who survived 12
months or longer (n = 3344), found similar associations. At
5 years from diagnosis, peri-diagnostic β-blocker users
lived on average 1.28 months longer than non-users $(95\%CI$
0.01-2.60 months). The results support the hypothesis that
β-blocker use improves EOC-specific survival in women with
EOC.},
keywords = {beta‐blockers (Other) / ovarian cancer (Other) /
population‐based (Other) / registry (Other) / survival
(Other)},
cin = {C020},
ddc = {610},
cid = {I:(DE-He78)C020-20160331},
pnm = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
pid = {G:(DE-HGF)POF4-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:39865612},
doi = {10.1002/ijc.35348},
url = {https://inrepo02.dkfz.de/record/298230},
}